Alere on Track to Launch HIV Viral Load Test Ex-US, File Isothermal Flu Assay with FDA in 2013 | GenomeWeb

Alere President and CEO Ron Zwanziger last week provided investors with an update on the development timeline for a pair of point-of-care nucleic acid testing plartforms, the company's first molecular diagnostics products.

During a conference call recapping Alere's second-quarter 2013 earnings, Zwanziger said that the company is on target to launch Alere Q, "our fully integrated, point-of-care, rapid, quantitative molecular platform" before the end of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."